Autopsy report · NCT05450562
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Cause of deathFunding or business, also safety
“Early discontinuation based on strategic sponsor decision not driven by any safety concerns”
Life of this trial
- Registered 2 months before it started.
- Ran for about 3 years 3 months before it stopped.
- 33 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Sanofi
- Sponsor type
- Industry
- Conditions
- Neoplasm
- Interventions
- SAR444200; Atezolizumab
- Participants
- 33
- Sites
- 13
- Countries
- Canada, China, Singapore, South Korea, United States
Trials that died the same way
- Goal Attainment and Physical Activity in People With Hemophilia A
“Early discontinuation based on sponsor decision not driven by any safety concerns.” - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
“Sponsor Decision to discontinue long-term follow-up” - Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
“Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.” - A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
“Strategic decision by Sponsor; not due to safety reasons” - Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
“Sponsor decision to terminate study early. Decision not based on safety concerns.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.